01	1		-
Sheet		ot	<u> </u>

FORM PTO-1449	9
---------------	---

LIST OF DISCLOSURES CITED BY APPLICANT

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.	Serial No.
P1759R1	09/589,395
Applicant	
Ashkenazi et al.	

(Use several sheets if necessary)

WO 99/11791

WO 99/33980

19 20 LICANT S

Filing Date Group
07 Jun 2000 1646

& MANEWARK FOREIGN PATENT DOCUMENTS Translation Examiner Class Subclass Yes Initials Document Number Date Country No 1 417,563 20.03.91 (ENGLISH ABSTRACT ATTACHED) 870,827 2 14.10.98 EPO RECEIVED WO 97/01633 16.01.97 PCT WO 97/25428 17.07.97 PCT DEC 29 2000 WO 97/46686 11.12.97 PCT WO 98/18921 07.05.98 PCT WO 98/28426 02.07.98 PCT ECH CENTER 1800/2900 WO 98/32856 30.07.98 PCT WO 98/35986 20.08.98 PCT 10 WO 98/39361 11.09.98 PCT GN/ WO 98/41629 24.09.98 PCT 11 12 WO 98/46643 22.10.98 PCT 13 WO 98/46751 22.10.98 PCT GN 14 WO 98/51793 19.11.98 PCT PCT 15 WO 99/02653 21.01.99 16 WO 99/04001 28.01.99 PCT WO 99/07738 18.02.99 PCT 17 GN WO 99/09165 25.02.99 PCT 18

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

		· · · · · · · · · · · · · · · · · · ·
	_ 21_	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of <u>Developing T</u> Cells" <u>Cold Spring Harbor Laboratory Symposium on Programmed Cell Death</u> (Abstr. No. 10) (1995)
	22	Armitage et al., "Molecular and biological characterization of a murine ligand for CD40" <u>Nature</u> 357(6373):80-82 (1992)
•	23	Aruffo et al., "CD44 is the Principal Cell Surface Receptor for Hyaluronate" <u>Cell</u> 61:1303-1313 (1990)
	24	Ashkenazi and Dixit, "Death receptors: signaling and modulation" <u>Science</u> 281(5381):1305-1308 (1998)
	25	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (1991)
	26	Ashkenazi et al., "Safety and antitumor activity of recombinant soluble Apo2 ligand" <u>Journal of Clinical</u> <u>Investigation</u> 104(2):155-162 (1999)
	27	Baldwin, A., "The NF-кВ and IкВ Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-683 (1996)
	28	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFB Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)

Examiner

Jusquits

11.03.99

08.07.99

PCT

PCT

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

, FORM I	PTO-1	U.S. Dept. of Commerce	Atty Docket No.	Serial No. 09/589, 395
s.		atent and Trademark Office	Applicant	
LIST	OF DIS	SCLOSURES CITED BY APPLICANTE: 2 6 2000 H	Ashkenazi et al.	
(Us	e sev	eral sheets if necessary)	Filing Date . 07 Jun 2000	Group 1646
·		OTHER DISCLOSURES (Including Author, Title, Date	, Pertinent Pages, etc.)	
	29	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Factor Receptor 1 and Fas(Apo-1/CD95)" Immunity 6:79-88 (1997)	th Sequence Homology t	to Tumor Necrosis
	30	Brockhaus et al., "Identification of two types of tumor necros: monoclonal antibodies" Proc. Natl. Acad. Sci. USA 87:3127-3131		human cell lines by
	31	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-89		nic Avian
	32	Browning et al., "Lymphotoxin β , a Novel Member of the TNF Familymphotoxin on the Cell Surface" Cell 72:847-856 (1993)	ly That Forms a Heter	comeric Complex with
-	33	Chicheportiche et al., "TWEAK, a new secreted ligand in the turinduces apoptosis" <u>Journal of Biological Chemistry</u> 272(51):3240		amily that weakly
	34	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-CD95" <u>Science</u> 274:990-992 (1996)	-Containing Receptor F	Related to TNFR-1 and
	35	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by 7 Interferon-γ" European Journal of Immunology 17:689-693 (1987)	Tumor Necrosis Factor	is Enhanced by
	36	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R. Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1		the Emerging TRAIL
	37	Degli-Esposti et al., "The Novel Receptor TRAIL-R4 Induces NF-Apoptosis, yet Retains an Incomplete Death Domain" Immunity 7:8	_	t TRAIL-Mediated
	38	Emery et al., "Osteoprotegerin is a receptor for the cytotoxic Chemistry 273(23):14363-14367 (1998)	ligand TRAIL" <u>Journal</u>	of Biological
	39	Gliniak and Le, "Tumor Necrosis Factor-related Apoptosis-induc Enhanced by the Chemoptherapeutic Agent CPT-11" <u>Cancer Research</u>	= -	Activity in Vivo Is
	40	Golstein, P., "Cell Death: TRAIL and its Receptors" <u>Curr. Biol</u>	7:R750-R753 (1997)	-
	41	Goodwin et al., "Molecular cloning and expression of the type 1 necrosis factor" Molecular & Cellular Biology 11:3020-3026 (195		eceptors for tumor
•	42	Gras et al., "BCMAp: an integral membrane protein in the Golgi Int. Immunology 7:1093-1106 (1995)	apparatus of human ma	ture B lymphocytes"
•	43	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Inv Lymphomas" <u>Blood</u> 85:3378-3404 (1995)	volvement in the Patho	ology of Malignant
	44	Hahne et al., "APRIL, a new ligand of the tumor necrosis factor Journal of Experimental Medicine 188(6):1185-1190 (1998)	family, stimulates t	umor cell growth"
	45	Hale et al., "Demonstration of in vitro and in vivo efficacy of TNF receptors expressed in E. coli" <u>J. Cell. Biochem.</u> (abstract (1991)	two biologically act only Supplement 15F;	ive human soluble P 424) pps. 113
	46	Hohmann et al., "Two different cell types have different major (TNFα)" Journal of Biological Chemistry 264(25):14927-14934 (19		umor necrosis factor
	47	Hymowitz et al., "Triggering cell death: the crystal structure receptor 5" Molecular Cell 4(4):563-571 (1999)	of Apo2L/TRAIL in a c	complex with death
	48	Itoh et al., "The polypeptide encoded by the cDNA for human celapoptosis" Cell 66:233-243 (1991)	l surface antigen Fas	can mediate
Examiner			Pate Considered	101
*Evamina	6	tial if reference considered, whether or not citation is in conformance with MPEP	600: draw line through eits	ation
		ormance and not considered. Include copy of this form with next communication		AUOH

Sheet	3	٥f	5
SHEEL	<u> </u>	Ui	

FORM	PTO-	1449 U.S. Dept. of Commerce	Atty Docket No.	Serial No.
,		Patent and Trademark Office	P1759R1	09/589,395
LIST	OF DI	SCLOSURES CITED BY APPLICANT DEC. 2 6 2000 4	Applicant Ashkenazi et al.	
/11	co cov	reral sheets if necessary)	Filing Date	Group
(0	36 36v	eral streets in necessary)	07 Jun 2000	1646
		OTHER DISCLOSUPER (Including Author, Title, Date,	Pertinent Pages, etc.)	
	49	Johnson et al., "Expression and Structure of the Human NGF Recep	otor" <u>Cell</u> 47:545-55	(1986)
	50	Kitson et al., "A Death-Domain-Containing Receptor that Mediate:	s Apoptosis" <u>Nature</u>	384:372-375 (1996)
	51	Kohno et al., "A second tumor necrosis factor receptor gene proceed necrosis factor inhibitor" Proc. Natl. Acad. Sci. USA 87:8331-83		rally occurring tumor
	52	Krammer et al., "Regulation of Apoptosis in the Immune System" (Curr. Op. Immunol. 6	5:279-289 (1994)
•	53	Laabi et al., "A new gene, BCM, on chromosome 16 is fused to the t(4;16)(q26;p13) translocation in a malignant T cell lymphoma"]	_	-
•	54	Laabi et al., "The BCMA gene, preferentially expressed during B transcribed" <u>Nucleic Acids Research</u> 22:1147-1154 (1994)	lymphoid maturation	, is bidirectionally
	55	Lewis et al., "Cloning and expression of cDNAs for two distinct demonstrate one receptor is species specific" Proc. Natl. Acad.		
	56	Loetscher et al., "Molecular Cloning and Expression of the Human Cell 61:351-359 (1990)	n 55 kd Tumor Necros	is Factor Receptor"
-	57	Lotz et al., "The nerve growth factor/tumor necrosis factor rece (1996)	eptor family" <u>J. Leu</u>	kocyte Biol. 60:1-7
	58	MacFarlane et al., "Identification and Molecular Cloning of Two TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (1997		the Cytotoxic Ligand
	59	Mackay et al., "Mice Transgenic for BAFF Develop Lymphocytic Dis Manifestations" <u>Journal of Experimental Medicine</u> 190:1697-1710	_	utoimmune
	60	Madry et al., "The characterization of murine BCMA gene defines factor receptor superfamily" Int. Immunology 10:1693-1702 (1998)		of the tumor necrosis
	61	Mallett et al., "Characterization of the MRC 0X40 Antigen of Act Molecule Related to Nerve Growth Factor Receptor" EMBO Journal		
•	62	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Tr 7:1003-1006 (1997)	runcated Death Domai	n" <u>Current Biology</u>
•	63	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Inc <u>Current Biology</u> 6(6):750-752 (1996)	dependent of FADD bu	t Blocked by CrmA"
	64	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Fact Domain and Activates Apoptosis and NF-KB" <u>Curr. Biol.</u> 6(12):1669		Contains a Death
		Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tu Interacts with Members of the TNFR-associated Factor Family and NF-KB and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14	Activates the Trans	cription Factors
	66	Marsters et al., "Identification of a ligand for the death-domain Biology 8(9):525-528 (1998)		
	67	Mongkolsapaya et al., "Cutting Edge: Lymphocyte inhibitor of TRA ligand): a new receptor protecting lymphocytes from the death li 160(1):3-6 (1998)	gand TRAIL" <u>Journal</u>	of Immunology
		Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Medi Receptor Family" <u>Cell</u> 87(3):427-436 (1996)	ated by a Novel Mem	ber of the TNF/NGF
Examine	7	Gursuro	te Considered	/
*Examine	er: Ini n conf	tial if reference considered, whether or not citation is in conformance with MPEP or commance and not considered. Include copy of this form with next communication to	609; draw line through ci o applicant.	tation

Sheet	4	of	5
SHEEL		01	J

. FORM	PTO-	1449 OIPF	U.S. Dept. of Commerce	Atty Docket No.	Serial No. 09/589,395
,			atent and Trademark Office	P1759R1	03/303,333
LIST	OF DIS	SCLOSURES CITED BY APPLICANT 2 6 201		Applicant Ashkenazi et al.	
L 101	0, 5,	veral sheets if necessary)	00 TI		Croun
(L	lse sev	veral sheets if necessary)		Filing Date 07 Jun 2000	Group 1646
		OTHER DISOLOGIUM	(Including Author, Title, Date	, Pertinent Pages, etc.)	
	69	Moore et al., "BLyS: member of the tu 285(5425):260-263 (1999)	mor necrosis factor famil	y and B lymphocyte s	timulator" <u>Science</u>
	70	Mukhopadhyay et al., "Identification That Activates Apoptosis, Nuclear Fac Chemistry 274:15978-15981 (1999)	tor-KB, and c-Jun NH2-Ter	ninal Kinase" <u>Journa</u>	
	71	Nagata and Golstein, "The Fas Death F	actor" <u>Science</u> 267:1449-1	456 (1995)	
	72	Nagata, S., "Apoptosis by Death Facto	r" Cell 88:355-365 (1997)		
•	73	Nocentini et al., "A new member of th inhibits T cell receptor-induced apop			
•	74	Nophar et al., "Soluble forms of tumo TNF-R, cloned using amino acid sequen soluble form of the receptor" EMBO Jo	ce data of its soluble fo urnal 9:3269-3278 (1990)	rm, encodes both the	cell surface and a
	75	Pan et al., "An Antagonist Decoy Rece 277:815-818 (1997)	ptor and a Death-domain C	ontaining Receptor f	or TRAIL" <u>Science</u>
	76	Pan et al., "Identification and funct receptor" FEBS Letters 431(3):351-356		DR6, a novel death	domain-containing TNF
	. 77	Pan et al., "The Receptor for the Cyt	otoxic Ligand TRAIL" <u>Scie</u>	<u>nce</u> 276:111-113 (199	7)
	78	Pan et al., "TRUNDD, a new member of Letters 424(1-2):41-45 (1998)	the TRAIL receptor family	that antagonizes TR	AIL signalling" <u>FEBS</u>
	79	Pitti et al., "Genomic amplification 396(6712):699-703 (1998)	of a decoy receptor for F	as ligand in lung an	d colon cancer" <u>Nature</u>
	80	Pitti et al., "Induction of Apoptosis Cytokine Family" <u>Journal of Biologica</u>			ecrosis Factor
	81	Radeke et al., "Gene transfer and mol 325:593-597 (1987)	ecular cloning of the rat	nerve growth factor	receptor" <u>Nature</u>
	82	Renshaw et al., "Humoral Immune Respondedicine 180:1889-1900 (1994)	nses in CD40 Ligand-defic	ient Mice" <u>Journal o</u>	f Experimental
•	83	Schall et al., "Molecular Cloning and 61:361-370 (1990)	Expression of a Receptor	for Human Tumor Nec	rosis Factor" <u>Cell</u>
	84	Schmid et al., "DNA Fragmentation: Ma. Lines, Lymphotoxin-secreting Helper T Proc. Natl. Acad. Sci. USA 83:1881-18	-cell Clones, and Cell-fr	Destruction Mediate ee Lymphotoxin-conta	ed by Cytotoxic T-cell ining Supernatant"
	85	Schneider et al., "BAFF, a Novel Liga: Journal of Experimental Medicine 189:		Factor Family, Stimu	lates B Cell Growth"
	86	Schneider et al., "Characterization o	-		
	87	Scholtissek and Grosse, "A plasmid ve β-galactosidase, a collagenase recogn			
	88	Screaton et al., "LARD: A new lymphoio alternative pre-mRNA splicing" <u>Proc.</u>			egulated by
Examine	r	Gurano		Pate Considered	01
*Examin	er: Ini n conf	tial if reference considered, whether or not citatic ormance and not considered. Include copy of th	on is in conformance with MPEP is form with next communication	609; draw line through of to applicant.	itation

Sheet	5	of	5
JIICCL		_ 0	

U.S. Dept. of Commerce Atty Docket No. Serial No. 09/589, 395	
Patent and Trademark Office	
LIST OF DISCLOSURES CITED BY APPLICANT / Ashkenazi et al	
(Use several sheets if necessary) Comparison of the property of the propert	
07 Jun 2000 1646	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)	
Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal	from
89 TRAIL" <u>Current Biology</u> 7:693-696 (1997)	
Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" 90 Science 277:818-821 (1997)	
Shu et al., "TALL-1 is a novel member of the TNF family that is down-regulated by mitogens" <u>J. Leuk</u> 91 <u>Biol.</u> 65:680-683 (1999)	ocyte
Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Densi 92 <u>Cell</u> 89:309-319 (1997)	ty"
Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral 93 Proteins" Science 248:1019-1023 (1990)	
Smith et al., "T2 Open reading frame from the shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. & Biophys. Res. Comm.</u> 176:335-342 (1991)	,
Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor induced by cytokines in carcinomas" EMBO Journal 8(5):1403-1410 (1989)	and
Tewari and Dixit, "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet.</u> 96 <u>Develop.</u> 6:39-44 (1996)	
Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)	.
Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region the shope fibroma virus genome" <u>Virology</u> 160:20-30 (1987)	n of
Verma et al., "Rel/NF-κB/IκB Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 99 9:2723-2735 (1995)	-
von Bulow and Bram, "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Fa 100 Receptor Superfamily" <u>Science</u> 278:138-141 (1997)	ictor
Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386	-5397
Walczak et al., "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in	1
102 vivo" Nature Med. 5:157-163 (1999)	
Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" Immunity 3:673-682 (1995)	
Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene" <u>Nature Genetics</u> 104 17:141-143 (1997)	Ŀ
Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen 105 co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)	
Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-35	1
Examiner Date Considered /	
11/02/UI	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation	